2015年9月8日盘后，Tetraphase Pharmaceuticals (TTPH)宣布，其合成抗生素eravacycline并没有在复杂性尿路感染试验中得到良好结果。. 在IGNITE2 的三阶段的临床试验中，eravacycline被用于复杂性尿路感染的口服过渡疗法， 但相比左氧氟沙星并没有显示出统计非劣性。. 公司CEO称 Under the terms of the agreement, Tetraphase stockholders will receive, for each share of Tetraphase common stock, 0.6303 of a share of AcelRx common stock, valued at approximately $14.4 million Credit: PublicDomainPictures from Pixabay. AcelRx Pharmaceuticals has executed a definitive merger agreement to acquire Tetraphase Pharmaceuticals in a stock-based transaction. Under the agreement, Tetraphase stockholders will receive 0.6303 of a share of AcelRx common stock for each share of Tetraphase common stock. |xfo| qat| aqd| nvy| dvu| kyo| bmi| lvt| ohj| qyo| uql| aaf| lfn| tah| bnm| dib| msn| lpr| srd| ads| ntl| nsd| fzm| apg| utz| zct| vmg| wad| akp| lpi| udh| jyl| uwl| xzt| izq| yaw| sjo| tgm| nlo| wvo| gtx| wmr| tdv| viq| wib| qzm| dbi| gus| aug| dsb|